Evidence map›Paper›PMID 40042661›Full record

ArticlePituitary2025

Dopamine agonists and weight changes in prolactinoma patients.

Nicholas Contento, David A Paul, G Edward Vates, Brent Johnson, Zachary Brehm, Ismat Shafiq

Abstract read
PubMed Publisher
In one paragraph

Article in Pituitary, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Nicholas ContentoDepartment of Emergency Medicine, University of Rochester Medical Center, Rochester, NY, USA. Nicholas_Contento@urmc.rochester.edu.
David A PaulDepartment of Neurological Surgery, University of Rochester Medical Center, Rochester, NY, USA.
G Edward VatesDepartment of Neurological Surgery, University of Rochester Medical Center, Rochester, NY, USA.
Brent JohnsonDepartment of Biostatistics and Computational Biology, University of Rochester Medical Center, Rochester, NY, USA.
Zachary BrehmDepartment of Biostatistics and Computational Biology, University of Rochester Medical Center, Rochester, NY, USA.
Ismat ShafiqDivision of Endocrinology, Diabetes, and Metabolism, University of Rochester Medical Center, 601 Elmwood Ave/ Box 693, Rochester, NY, 14642, USA.ORCID https://orcid.org/0000-0002-1367-5053

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeProlactinomas, the predominant pituitary adenoma type, are primarily treated with dopamine agonists to decrease prolactin levels and tumor size. The use of dopamine agonists has been shown to improve metabolic parameters and lead to weight loss in prolactinoma patients. However, the data is conflicting and sparse. In the current study, we aim to review weight variations in prolactinoma patients treated with dopamine agonists.

methodsWe identified prolactinoma patients referred to one pituitary clinic between 2010 and 2020. Data from prolactinoma patients treated with dopamine agonist therapy were retrospectively collected over the span of 1 year. Serum prolactin and weight measurements were obtained at the time of diagnosis and at 3-months, 6-months, and 12-month time points. We also collected information on the patient's age, sex, BMI, diabetes history, and dopamine agonist treatment regimen.

results91 patients with prolactinoma treated with dopamine agonist were included in the study. Among the 91 patients, 47 were females and 44 were males. The average age for females was 30.5 years and for males were 49 years. The average BMI in females was 31.02 kg/m

conclusionsThe use of dopamine agonists for a duration of about 12 months did not result in statistically significant weight loss among patients with prolactinoma.

Indexed as

Body WeightDopamine AgonistsPituitary NeoplasmsProlactinomaAdultFemaleHumansMaleMiddle AgedProlactinRetrospective StudiesYoung AdultDopamine AgonistsProlactinDopamine agonistPituitary adenomasProlactinWeight

Identifiers

PMID40042661

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.